Short-acting analogs of somatostatin can be used up to 24 hr before imaging with Ga 68 dotatate.Image patients with Ga 68 dotatate PET just prior to dosing with long-acting analogs of somatostatin.Nonradioactive somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate.A negative scan after administration of Ga 68 dotatate in patients who do not have history of NETs, including in patients suspected of ectopic ACTH-secreting tumors, does not rule out the presence of NETs.PET images with Ga 68 dotatate should be interpreted visually and the uptake may need to be confirmed by histopathology or other assessments to confirm NET diagnosis.Increased uptake might be seen in sites of splenosis or other pathologic conditions (eg, thyroid disease or subacute inflammation) or might occur as a normal physiologic variant (eg, uncinate process of the pancreas).Uptake can also be seen in a variety of other tumor types (eg, those derived from neural crest tissue).Uptake of Ga 68 dotatate reflects somatostatin receptor density in NETs.Ensure safe handling and preparation procedures to protect patients and healthcare workers from unintentional radiation exposure.Contributes to a patient’s overall long-term cumulative radiation exposure long-term cumulative radiation exposure associated with increased cancer risk.Avoid close contact with infants and pregnant women during first 12 hours after administration of Ga 68 dotatate.Short-acting somatostatin analogs can be used up to 24 hr before imaging with Ga 68 dotatate. Image patients with Ga 68 dotatate PET just prior to dosing with long-acting somatostatin analogs. Somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate and may affect imaging. Monitor Closely (1)pasireotide decreases effects of gallium Ga 68 dotatate by receptor binding competition.

Monitor Closely (1)octreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Monitor Closely (1)lanreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Pasireotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Octreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Lanreotide decreases effects of gallium Ga 68 dotatate by receptor binding competition.

Netspot kit